Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Arvinas Partner to Develop CDx For Prostate Cancer Drug

NEW YORK – Roche's Foundation Medicine announced on Sunday that it is collaborating with Arvinas to develop its liquid biopsy test as a companion diagnostic for an investigational prostate cancer drug.

Financial and other terms of the strategic collaboration were not disclosed.

Under the deal, Foundation and Arvinas will develop FoundationOne Liquid CDx as a companion diagnostic for use with Arvinas' bavdegalutamide (ARV-110), an investigational protein degrader targeting the androgen receptor, Foundation said in a statement. Bavdegalutamide is a proteolysis-targeting chimera that works by using the body's natural protein disposal system to selectively degrade and remove disease-causing proteins. 

The drug is being developed for the possible treatment of patients with metastatic castration-resistant prostate cancer who have progressed on existing therapies. 

"Bringing our capabilities to this emerging area of biotechnology sets us on an exciting path to deepen our collective understanding of cancer biology and deliver more novel treatment options to patients now and in the future," FMI's Chief Biopharma Business Officer Sanket Agrawal said in a statement.

The Scan

Monkeypox Meeting

As the World Health Organization gets ready to hold another monkeypox meeting, the US distributes vaccines and increases its testing capacity.

CRISPR's Softer Side

A homologous chromosome-templated repair approach to gene editing relies on versions of the Cas9 enzyme that cut a single DNA strand.

Pickled? No Problem

Researchers come up with an approach for extracting DNA from archived museum specimens. 

Nature Papers on Long Reads for Bacterial Genomes, Zebrafish Atlas, Hypothalamic Aging in Mammals

In Nature this week: near-finished microbial genomes without polishing, zebrafish functional annotation program, and more.